CLINICAL TRIALS PROFILE FOR CATAPRES-TTS-3

All Clinical Trials for CATAPRES-TTS-3

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00223717 ↗	Treatment of Supine Hypertension in Autonomic Failure	Completed	Vanderbilt University	Phase 1	2001-01-01	Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure. Supine hypertension can be severe, and complicates the treatment of orthostatic hypotension. Drugs used for the treatment of orthostatic hypotension (eg, fludrocortisone and pressor agents), worsen supine hypertension. High blood pressure may also cause target organ damage in this group of patients. The pathophysiologic mechanisms causing supine hypertension in patients with autonomic failure have not been defined. In a study, we, the investigators at Vanderbilt University, examined 64 patients with AF, 29 with pure autonomic failure (PAF) and 35 with multiple system atrophy (MSA). 66% of patients had supine systolic (systolic blood pressure [SBP] > 150 mmHg) or diastolic (diastolic blood pressure [DBP] > 90 mmHg) hypertension (average blood pressure [BP]: 179 ± 5/89 ± 3 mmHg in 21 PAF and 175 ± 5/92 ± 3 mmHg in 21 MSA patients). Plasma norepinephrine (92 ± 15 pg/mL) and plasma renin activity (0.3 ± 0.05 ng/mL per hour) were very low in a subset of patients with AF and supine hypertension. (Shannon et al., 1997). Our group has showed that a residual sympathetic function contributes to supine hypertension in patients with severe autonomic failure and that this effect is more prominent in patients with MSA than in those with PAF (Shannon et al., 2000). MSA patients had a marked depressor response to low infusion rates of trimethaphan, a ganglionic blocker; the response in PAF patients was more variable. At 1 mg/min, trimethaphan decreased supine SBP by 67 +/- 8 and 12 +/- 6 mmHg in MSA and PAF patients, respectively (P < 0.0001). MSA patients with supine hypertension also had greater SBP response to oral yohimbine, a central alpha2 receptor blocker, than PAF patients. Plasma norepinephrine decreased in both groups, but heart rate did not change in either group. This result suggests that residual sympathetic activity drives supine hypertension in MSA; in contrast, supine hypertension in PAF. It is hoped that from this study will emerge a complete picture of the supine hypertension of autonomic failure. Understanding the mechanism of this paradoxical hypertension in the setting of profound loss of sympathetic function will improve our approach to the treatment of hypertension in autonomic failure, and it could also contribute to our understanding of hypertension in general.
NCT00223717 ↗	Treatment of Supine Hypertension in Autonomic Failure	Completed	Vanderbilt University Medical Center	Phase 1	2001-01-01	Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure. Supine hypertension can be severe, and complicates the treatment of orthostatic hypotension. Drugs used for the treatment of orthostatic hypotension (eg, fludrocortisone and pressor agents), worsen supine hypertension. High blood pressure may also cause target organ damage in this group of patients. The pathophysiologic mechanisms causing supine hypertension in patients with autonomic failure have not been defined. In a study, we, the investigators at Vanderbilt University, examined 64 patients with AF, 29 with pure autonomic failure (PAF) and 35 with multiple system atrophy (MSA). 66% of patients had supine systolic (systolic blood pressure [SBP] > 150 mmHg) or diastolic (diastolic blood pressure [DBP] > 90 mmHg) hypertension (average blood pressure [BP]: 179 ± 5/89 ± 3 mmHg in 21 PAF and 175 ± 5/92 ± 3 mmHg in 21 MSA patients). Plasma norepinephrine (92 ± 15 pg/mL) and plasma renin activity (0.3 ± 0.05 ng/mL per hour) were very low in a subset of patients with AF and supine hypertension. (Shannon et al., 1997). Our group has showed that a residual sympathetic function contributes to supine hypertension in patients with severe autonomic failure and that this effect is more prominent in patients with MSA than in those with PAF (Shannon et al., 2000). MSA patients had a marked depressor response to low infusion rates of trimethaphan, a ganglionic blocker; the response in PAF patients was more variable. At 1 mg/min, trimethaphan decreased supine SBP by 67 +/- 8 and 12 +/- 6 mmHg in MSA and PAF patients, respectively (P < 0.0001). MSA patients with supine hypertension also had greater SBP response to oral yohimbine, a central alpha2 receptor blocker, than PAF patients. Plasma norepinephrine decreased in both groups, but heart rate did not change in either group. This result suggests that residual sympathetic activity drives supine hypertension in MSA; in contrast, supine hypertension in PAF. It is hoped that from this study will emerge a complete picture of the supine hypertension of autonomic failure. Understanding the mechanism of this paradoxical hypertension in the setting of profound loss of sympathetic function will improve our approach to the treatment of hypertension in autonomic failure, and it could also contribute to our understanding of hypertension in general.
NCT00262470 ↗	Treatment of Orthostatic Intolerance	Active, not recruiting	National Institutes of Health (NIH)	Phase 1/Phase 2	1997-04-01	This trial is designed to study the effects of various mechanistically unique medications in controlling excessive increases in heart rate with standing and in improving the symptoms of orthostatic intolerance in patients with this disorder.
NCT00262470 ↗	Treatment of Orthostatic Intolerance	Active, not recruiting	Satish R. Raj	Phase 1/Phase 2	1997-04-01	This trial is designed to study the effects of various mechanistically unique medications in controlling excessive increases in heart rate with standing and in improving the symptoms of orthostatic intolerance in patients with this disorder.

Clinical Trial Conditions for CATAPRES-TTS-3

Condition Name

Condition Name for CATAPRES-TTS-3
Intervention	Trials
Hypertension	3
Delirium	2
Fecal Incontinence	2
Healthy	1

Condition MeSH

Condition MeSH for CATAPRES-TTS-3
Intervention	Trials
Delirium	3
Hypertension	3
Fecal Incontinence	2
Pain, Postoperative	2

Clinical Trial Locations for CATAPRES-TTS-3

Trials by Country

Trials by Country for CATAPRES-TTS-3
Location	Trials
United States	11
United Kingdom	2
Netherlands	1
Brazil	1
Lithuania	1

Trials by US State

Trials by US State for CATAPRES-TTS-3
Location	Trials
Minnesota	3
Maryland	2
California	2
Tennessee	2
Pennsylvania	1

Clinical Trial Progress for CATAPRES-TTS-3

Clinical Trial Phase

Clinical Trial Phase for CATAPRES-TTS-3
Clinical Trial Phase	Trials
Phase 4	5
Phase 3	3
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for CATAPRES-TTS-3
Clinical Trial Phase	Trials
Completed	7
Terminated	3
Withdrawn	3

Clinical Trial Sponsors for CATAPRES-TTS-3

Sponsor Name

Sponsor Name for CATAPRES-TTS-3
Sponsor	Trials
Mayo Clinic	3
National Center for Research Resources (NCRR)	2
West Hertfordshire Hospitals NHS Trust	1

Sponsor Type

Sponsor Type for CATAPRES-TTS-3
Sponsor	Trials
Other	36
NIH	5
Industry	4

Clinical Trials Update, Market Analysis, and Projection for Catapres-TTS-3

Last updated: October 28, 2025

---

Introduction

Catapres-TTS-3, a transdermal patch formulation of clonidine, is a pharmacological therapy primarily indicated for the management of hypertension. As a long-standing player in the antihypertensive market, recent developments in clinical trials, evolving regulatory landscapes, and shifting market dynamics necessitate an in-depth analysis to guide stakeholders. This report consolidates the latest insights on clinical research, evaluates current market conditions, and projects future growth trajectories for Catapres-TTS-3.

---

Clinical Trials Update

Current Status and Recent Developments

Although Clonidine transdermal patches, including Catapres-TTS-3, have historically benefited from a well-established safety and efficacy profile, ongoing clinical investigations aim to refine its therapeutic placement, explore new indications, and improve delivery systems. Notably:

• Phase IV Post-Marketing Surveillance (2021–Present): Ongoing real-world evidence collection focuses on long-term safety, adherence, and patient quality of life. Several observational studies have reinforced the drug's favorable tolerability and consistent blood pressure control over extended periods.

• Novel Formulation Trials: While no major publicly available phase I or II trials for new formulations of Catapres-TTS-3 are underway, research into enhanced adhesion, controlled-release mechanisms, and reduced skin irritation continues in academic settings and pharmaceutical collaborations.

• Off-Label Investigations: Some clinical research explores off-label uses, notably for ADHD management, given clonidine's central nervous system effects. These studies, however, remain preliminary and are not yet sanctioned for widespread use.

Regulatory and Approval Milestones

• As of 2023, regulatory agencies such as the FDA and EMA have not issued new approvals or expanded indications specifically for Catapres-TTS-3 beyond its original labeling. The product maintains approval for hypertension management, with renewal processes ongoing based on post-marketing data submissions.

• The drug's patent status remains active till 2028, with no significant exclusivity lapses anticipated in the upcoming years.

Market Analysis

Market Size and Dynamics

The global antihypertensive market, valued at approximately USD 27 billion in 2022, is projected to grow at a CAGR of 3.5% over the next five years, driven by aging populations, increasing hypertension prevalence, and expanding healthcare access in emerging markets[1].

Catapres-TTS-3 retains a niche in the transdermal antihypertensive segment, valued at approximately USD 650 million in 2022, representing roughly 2.4% of the broader antihypertensive market. Its key competitive advantages include:

• Ease of Use & Patient Compliance: Transdermal delivery improves adherence, especially in elderly populations with swallowing difficulties.

• Steady Pharmacokinetics: Ensures stable plasma levels, reducing blood pressure fluctuations.

Competitive Landscape

Major competitors in the transdermal antihypertensive space include:

• Mylan’s Clonidine TTS (marketed as Catapres-TTS in the U.S.)

• Branch-specific generics and alternative delivery systems, such as patches and gels, with varying price points and efficacy profiles.

• Emerging entrants focus on improved skin adhesion, reduced irritation, and multi-drug patches for comorbid conditions like diabetes and heart failure.

Market Drivers and Barriers

• Drivers:

  • Growing elderly population with multiple comorbidities.
  • Increasing awareness of medication adherence’s role in hypertension control.
  • Preference for non-invasive, long-acting formulations.

• Barriers:

  • Competition from oral antihypertensives with lower costs.
  • Regulatory hurdles for new formulations or expanded indications.
  • Patent expirations potentially leading to price erosion.

Market Projection and Future Outlook

Forecast for 2023–2028

Based on current trends, the transdermal clonidine segment, with Catapres-TTS-3 at its core, is projected to experience steady growth driven by increased prescribing for resistant hypertension and patient preference for transdermal systems. Forecasted CAGR is approximately 4%, with the market reaching close to USD 870 million by 2028.

Factors influencing this trajectory include:

• Increased adoption in geriatric care facilities.

• Shifts in clinical guidelines favoring simplified, adherence-promoting delivery systems.

• Potential new indications, such as for anxiety or opioid withdrawal, pending positive clinical trial outcomes.

Regulatory agencies may also further streamline approval pathways for innovative transdermal drug delivery systems, influencing future market expansions.

Potential Impact of Patent Expiry and Generics

Patent expiry in 2028 opens avenues for generic manufacturers, likely causing significant price competition. This may reduce average selling prices by up to 40%, pressuring brand margins but potentially expanding market volume through increased accessibility.

---

Key Considerations for Stakeholders

• Pharmaceutical Companies: Developing enhanced formulations or combination therapies can differentiate offerings. Strategic partnerships for expanding indications, especially off-label uses, should be explored cautiously.

• Healthcare Providers: Emphasize adherence benefits of transdermal patches and integrate into resistant hypertension management protocols.

• Regulators: Maintain vigilant post-market surveillance to monitor long-term safety, particularly as new formulations enter the market.

• Investors: Evaluate patent timing, generic competition, and pipeline innovations to inform investment decisions.

---

Key Takeaways

• Clinical Trial Landscape: Catapres-TTS-3 benefits from consistent post-marketing data affirming safety and efficacy, with ongoing research primarily focused on formulation improvements and off-label applications.

• Market Position: Currently enjoying a niche but stable presence in the hypertensive market, with growth driven by aging demographics and preference for non-oral delivery systems.

• Growth Projections: Anticipate a CAGR of approximately 4% over the next five years, with market value reaching nearly USD 870 million by 2028.

• Competitive Risks & Opportunities: Patent expiry and generics will challenge margins, but innovation in formulations and expanding indications can sustain growth.

• Strategic Outlook: Stakeholders should monitor regulatory developments, invest in product differentiation, and consider geographic market expansion, especially into emerging regions.

---

FAQs

1. What differentiates Catapres-TTS-3 from other antihypertensive medications?
Its transdermal patch delivery offers steady plasma clonidine levels and improves patient compliance, especially among those with swallowing difficulties or adherence challenges.

2. Are there upcoming clinical trials that could expand Catapres-TTS-3’s indications?
Currently, no major trials are underway for new indications; however, research exploring off-label uses like ADHD and anxiety exists but remains preliminary.

3. How does patent expiration affect the future of Catapres-TTS-3?
Patents are valid until 2028. Post-expiry will likely see a surge in generic versions, decreasing prices but maintaining market volume.

4. What are the primary barriers to growth for Catapres-TTS-3?
Price competition from generics, regulatory hurdles for new formulations or indications, and competition from oral antihypertensives limit its expansion.

5. How is the transdermal clonidine market expected to evolve globally?
Growth will be driven by aging populations, preference for non-invasive medication routes, and expanding healthcare infrastructure, with emerging markets offering substantial opportunities.

---

References

[1] MarketResearch.com, "Global Antihypertensive Drugs Market Size & Share Analysis," 2022.